Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: a case report

Lung cancer was a leading cause of death worldwide, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer [1]. Anaplastic lymphoma kinase (ALK) gene rearrangements are observed in 3.4-6.7 % of NSCLC patients [2,3], especially in mild or non-smokers [4]. Echinoderm microtubule-associated protein-like 4 gene (EML4)-ALK variant is the most frequent fusion in NSCLC [5], and more ALK fusions are detected with explosive advances in next-generation sequencing (NGS). Currently, ALK tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with ALK-rearranged NSCLC.

Source: Lung Cancer - November 5, 2021 Category: Cancer & Oncology Authors: Qi Liang, Huanhuan Xu, Yiqian Liu, Weiming Zhang, Chongqi Sun, Meng Hu, Yizhi Zhu, Shanyue Tan, Xian Xu, Sumeng Wang, Lingxiang Liu Source Type: research